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Abstract
The cannabinoid system is known to be involved in the regulation of inflammatory processes. Therefore, drugs targeting
cannabinoid receptors are considered as candidates for anti-inflammatory and tissue protective therapy. We demonstrated
that the prototypical cannabinoid agonist R(+)WIN55,212-2 (WIN) reduced the secretion of matrix metalloproteinase-9
(MMP-9) in a murine model of cigarette-smoke induced lung inflammation. In experiments using primary cells and cell lines
of the monocyte-macrophage-system we found that binding of the cannabinoid-receptor agonist WIN to a stereo-selective,
specific binding site in cells of the monocyte-macrophage-system induced a significant down-regulation of MMP-9 secretion
and disturbance of intracellular processing, which subsequently down-regulated MMP-9 mRNA expression via a ERK1/2-
phosphorylation-dependent pathway. Surprisingly, the anti-inflammatory effect was independent from classical
cannabinoid receptors. Our experiments supposed an involvement of TRPV1, but other yet unidentified sites are also
possible. We conclude that cannabinoid-induced control of MMP-9 in the monocyte-macrophage system via a cannabinoid-
receptor independent pathway represents a general option for tissue protection during inflammation, such as during lung
inflammation and other diseases associated with inflammatory tissue damage.
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Introduction
In the last years, several in vitro, in vivo and clinical studies
suggested that the endocannabinoid system (ECS) is a crucial
participant in the control and regulation of inflammation, where it
interferes at different points and in key mechanisms of the
orchestrated immunological network. Cannabinoids inhibit the
release of proinflammatory cytokines such as TNF-a, IL-1-b [1,2]
IL-2 (2), IL-6 and IL-8 [3,4], and they apparently stimulate nitric
oxide release [5]. It has been proposed that endocannabinoids are
chemo attractants, which first help to attract macrophages to the
site of tissue damage [6]. Beyond inflammatory mediators [7],
essential immunological functions such as migration [8], chemo-
taxis [9] and immune cell apoptosis [10] are affected by
cannabinoid signaling. Numerous in vitro and in vivo studies suggest
that drugs targeting cannabinoid receptors or modulating tissue
levels of endocannabinoids represent promising candidates for
treatment of inflammatory conditions [11,12,13].
Throughout the animal kingdom the endocannabinoid system is
a highly conserved signaling system, and it is already developed in
invertebrates [14] and plants. The fact that even plants possess a
signal transduction system which exceedingly resembles the
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endocannabinoid system in animals, underlines the success of this
evolutionary achievement [15]. Both cannabinoid receptor 1
(CB1) and cannabinoid receptor 2 (CB2) are seven-transmem-
brane Gi/o -protein-coupled receptors, but distinct in distribution
and physiological function. CB1 receptors are one of the most
abundant G-protein-coupled receptors in the brain and mostly
expressed on neurons of the neocortex, hippocampus, basal
ganglia, cerebellum and brainstem [16], where they also mediate
most of the effects of D9-tetrahydrocannabinol (THC) [16,17].
CB2 receptors mediate anti-inflammatory effects in cells of the
immune system [7,18]. However, several studies have shown that
some effects of cannabinoid ligands cannot be attributed to CB1 or
CB2 receptors and several sites distinct from CB receptors, where
at least some cannabinoid receptor ligands show activity, have
been identified [19]. Among these sites are the non-selective cation
channel transient receptor potential vanilloid type 1 (TRPV1)
[20], the G protein-coupled orphan receptor GPR55 [21,22] and
the family of peroxisome proliferator-activated receptors (PPARs)
[23]. Today pharmacological modulations of the cannabinoid
system offer the opportunity for therapeutic intervention and the
possibility to control or limit inflammation and to reduce tissue
damage [24,25].
Severe tissue damage and destruction during inflammatory
conditions are often induced by collagen degrading proteins of the
matrix metalloproteinase (MMP) family. These proteins are
involved in the breakdown of extracellular matrix during
development, tissue remodeling and cell migration during
physiological conditions. The family of MMPs comprises almost
30 members of zink-dependent endopeptidases. Together they are
capable of digesting all components of the basal membrane and
the extracellular matrix and they constitute a crucial element of
immune regulation [26]. MMPs are secreted by macrophages and
other types of migrating cells and their obvious function is to
enable cells to overcome physical barriers and allow them to
infiltrate tissue [27]. Furthermore, MMPs have important
immunregulatory functions including modulation of cytokines,
chemokines and leukocyte recruitment [26,28]. MMPs are
considered to be involved in numerous cell functions in health
and disease [29,30,31]. Among all MMPs, MMP-9 is regarded as a
higher-ranking immune-modulatory element [32] and its secretion
is enhanced in response to inflammatory stimuli such as TNF-a
[33]. In order to avoid destructive activity, MMP-9 is regulated
tightly at different levels: MMP-9 is secreted in a zymogenic form
(92 kDa) following proteolytic cleavage yielding the active form
(85 kDa) [34]. Other control-mechanisms are transcriptional
regulation [35], post-translational regulation, regulation of the
secretory process [36], and regulation by inhibitors of matrix
metalloproteinases (TIMPs) [37]. MMP-9 plays a physiological
role in tissue reorganization and bone metabolism [38,39,40],
where it represents one of the most abundant proteases in
osteoclasts [39,41]. MMP-9 is furthermore involved in the
pathophysiological process underlying many inflammatory diseas-
es: It was already shown in 1999 that genetically MMP-9-deficient
mice develop more severe experimental autoimmune encephalo-
myelitis (EAE) than wildtype littermates [42]. In multiple sclerosis
MMP-9 causes increased permeability of the blood brain barrier,
leading to greater inflammatory infiltration and it subsequently
enhances demyelinisation and neuronal damage [43]. Inhibition of
MMP-9 is discussed as a therapeutic strategy for multiple sclerosis,
since inhibition of MMP-9 by Interferon-b led to reduced
transmigration and decreased permeability of the blood brain
barrier in patients [43,44,45]. In cardiovascular diseases MMP-9
contributes to the development of artheriosclerotic plaques and the
resulting risk of strokes and cardiac infarction [46]. Furthermore,
MMP-9 is involved in the pathogenesis of inflammatory bowel
disease, rheumatoid arthritis and chronic obstructive pulmonary
disease (COPD) [43,47,48]. Thus, MMP-9 is a key mediator of
tissue destruction in many diseases marked by inflammatory tissue
damage, and inhibition of MMP-9 seems a promising strategy to
treat inflammatory diseases.
Because cannabinoids are able to modulate secretion of MMPs
in different cell types such as epithelial cells [49], fibroblasts [50]
and glioma cells [51], we aimed to investigate if macrophageal
secretion of MMP-9 can be modulated by cannabinoids. In our
study we used the aminoalkylindole compound WIN
(R(+)WIN55,212-2= [(3R)-2,3-dihydro-5-methyl-3-(4-morpholi-
nylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenyl-
methanone, monomethanesulfonate, CAS No 131543-23-2), a
prototypical cannabinoid, which is an agonist of cannabinoid
receptor 1 and 2 and has been widely used to study cannabinoid
signalling in vitro as well as in vivo. Its in vitro effects comprise
modulation of chemokines, migration and proliferation [52,53,54].
Importantly, during the last years a rising number of in vivo studies
have shown therapeutic effects of WIN in animal-models of
inflammatory pain, arteriosclerosis and multiple sclerosis
[55,56,57,58]. Interestingly, some of its beneficial effects seem to
be independent of cannabinoid receptors 1 and 2 [59,60].
We combined investigations in primary cells and cell lines of the
monocyte-macrophage system. We also looked at an animal model
for lung inflammation. In these we examined the regulation of
MMP secretion by cannabinoids and its underlying cellular
mechanism in order to evaluate the potential of cannabinoid
compounds in the treatment of diseases that comprise MMP-9-
mediated tissue-destruction.
Materials and Methods
Reagents and Supplements
If not stated differently, reagents were purchased from Sigma
Aldrich (Buchs, Switzerland). S(–)-WIN 55,212-3 and (R)-(+)-WIN
55,212-2 were dissolved in Dimethyl sulfoxide (DMSO) (10 mM).
Phorbol-12-myristat-13-acetat (PMA) was dissolved in DMSO
(1 mg/ml), pertussis toxin (Calbiochem, Darmstadt, Germany)
was received as glycerol solution of 0.5 mg/ml, AM630 and
AM251 (Tocris Laboratories, Bristol, United Kingdom) were
dissolved in DMSO (100 mM), LPS (lipopolysaccharide) from E.
coli 0111:B4 (Sigma) was dissolved in water (1 mg/ml), 1,3-
Dimethoxy-5-methyl-2-[(1R,6R)-3-methyl-6-(1-methylethenyl)-2-
cyclohexen-1-yl] benzene (O-1918) (Tocris) was dissolved in
DMSO (100 mM), and (R)-(+)-trans-4-(1-Aminoethyl)-N-(4-Pyri-
dyl)cyclohexanecarboxamide dihydrochloride monohydrate
(Y27632) (Calbiochem) was purchased as a 5 mM aqueous
solution. Dexamethasone was dissolved in ethanol (EtOH)
(1 mg/ml). Receptor Activator of NFkB Ligand (RANK-L) and
human macrophage colony stimulating factor (M-CSF) (Pepro-
Tech, London, UK) were dissolved in demineralized water
(50 mg/ml and 25 mg/ml), human TGF-b 1 (PeproTech) was
dissolved in phosphate buffered saline (137 mM NaCl, 2.7 mM
KCl, 100 mM Na2HPO4, 2 mM KH2PO4) (PBS) and 2 mg/ml
bovine serum albumin (BSA) (5 mg/ml). Capsaicin and Capsaze-
pine were dissolved in EtOH (1 mM and 50 mM). Prior to
treatment the substances were further diluted if necessary. In the
cell culture experiments with the mentioned substances, the
solvent concentrations never exceeded 0.1%. Vehicle controls
were performed using the same solvent concentrations as in the
experiments with the treatment-substances.
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Mouse Model of Smoke-induced Lung Inflammation
Male mice (C57BL/6J) aged 8–10 weeks were used (with a
weight of 20–25 g) and obtained from Charles River (Sulzfeld,
Germany). All animal experimentation/studies were performed in
accordance with the national animal protection rules and they
were approved by the local governmental authority (Ministerium
fu¨r Landwirtschaft, Umwelt und la¨ndliche Ra¨ume des Landes
Schleswig-Holstein) under the permission no. V 312-72241.123-15
(74-7/10). The mice were housed in groups of 8–10 in individually
ventilated microisolator-cages (IVC). Room temperature was kept
at 22u–24uC, and relative humidity at 40–50%. Food and water
were supplied ad libitum. WIN55212-2 mesylate (Cay100009023-
50) was purchased from Caymen Chemicals. All drugs prepared in
DMSO were injected intraperitoneally (3% DMSO) in volumes of
200 ml/animal. The solvent/vehicle alone had no effect on the
response in the in vivo studies. WIN55212-2 mesylate was given i.p.
daily 1 hour prior to cigarette smoke (CS) exposure. Mice
(n=8210/group) were exposed (whole body) to CS (Reference
Cigarettes 2R4F with filter, University of Kentucky, Lexington,
KY, USA) 2 times a day for 1 h with 1 h smoke-free intervals, for
4 days. Control groups were exposed to air. For exposure mice
were separated in custom-made steal cages to assure the whole
body exposure of each mouse. The smoke was produced by the
burning of cigarettes in a smoke generator (15 puffs/min) and was
introduced into the exposure chamber with the airflow generated
by a mechanical ventilator at a rate of 1.5 l/min. The smoke
stream was diluted with compressed air (40 l/min). The total
particulate matter in the CS was max. 700 mg/l.
Bronchoalveolar Lavage
One hour after the last CS exposure the mice were sacrificed by
intraperitoneal injection of an overdose of thiopental (Trapanal H).
The trachea was exposed and cannulated with a tracheal catheter.
Bronchoalveolar lavage (BAL) was performed by instilling 2 x
0.8 mL of phosphate buffered saline (1 x PBS; Invitrogen cat
no18912-014) supplemented with 0.5% bovine serum albumin
(BSA) (Serva, Heidelberg, Germany). Total and differential cell
count was determined automatically using a XT-2000iV haemo-
cytometer (Sysmex, Norderstedt, Germany). The gates for the
differentiation of cell types were adjusted to reflect the microscopic
analysis of cytospin slides according to standard morphological
criteria. The BAL fluid was centrifuged (1400 rpm, 10 min, 4uC).
Supernatants were stored at 220uC.
Cell Culture of U937 Monocytic Cells
U937 monocytic cells (ATCC Manassas, VA, USA) were grown
in RPMI 1640 medium (Biochrom, Berlin, Germany) supple-
mented with 10% fetal bovine serum (FBS) (Biochrom), penicillin
(100 U/ml) and streptomycin (100 mg/ml) in a 5% CO2
atmosphere at 37uC. Cell density was 0.15 - 2 x 106 cells/ml,
medium was changed every third day. Differentiation into
macrophagial cells was induced by treatment with 100 nM PMA
for 72 h at a cell concentration of 0.4 x 106 cell/ml in cell culture
plates (Nunc, Wiesbaden, Germany). PMA was first diluted in
DMSO at 100 mM and then added to the cells in a dilution of
1:1000, so that the final concentration of DMSO in the culture
medium was 0.1%, which elicited no signs of cell damage as
evaluated by trypan blue staining. After PMA-treatment the
culture medium was exchanged with medium lacking PMA and
the cells were allowed to recover for 24 h. For inflammatory
activation cells were subsequently treated with 1 mg/ml lipopoly-
saccharide (LPS) (stock concentration was 100 mg/ml in demin-
eralized water) and subjected to experiments. As a component of
gram-negative bacteria LPS is a potent stimulator of inflammation
and leads to secretion of TNF-a und IL-1-b [61,62]. Signaling
depends on the membrane-anchored receptor CD14 and Toll-like
receptor (TLR) 4, which are functionally abundant on U937 cells
[63,64]. Cells differentiated and activated as described are referred
to as U937-macrophages. The activated status of these cells was
checked regularly with TNF-a-Enzyme Linked Immunosorbent
Assay (ELISA) [65,66].
Cell Culture of Primary Human Macrophages
Primary human macrophages were isolated from blood donated
by healthy volunteers (Blutspendedienst Zu¨rich, www.zhbsd.ch)
using ‘‘buffy coats’’, a byproduct in the manufacturing of red
blood cells and platelet concentrate from whole blood donation.
All donors have signed an informed consent stating that blood or
certain components may be anonymously used for research
purposes (see www.zhbsd.ch) ). 200 ml blood containing 10 U/
ml heparin was supplemented with 100 ml RPMI medium.
Peripheral blood monocytic cells (PBMCs) were separated by
density centrifugation (25 min, 500 g) through Ficoll-Paque (GE
Healthcare, Glattbrugg, Switzerland). PBMCs were washed twice
in RPMI and PBS (w/o Ca2+ and Mg2+) containing 0.5% bovine
serum albumin each. Subsequently cells were suspended in RPMI
with 10% fetal bovine serum, penicillin (100 U/ml) and
streptomycin (100 mg/ml) and seeded at 3 x 106 cells/ml in cell
culture plates. After 1 h incubation under cell culture conditions,
macrophageal cells had adhered to the flasks and non-adherent
cells were removed. Cells were kept under culture conditions for
three more days before they were subjected to experiments.
Cell Culture of Human Osteoclasts
Osteoclasts were generated from human PBMCs. PBMCs were
isolated from buffy coats which were obtained from the blood
donation center Zurich (Blutspende Zu¨rich, Schlieren, Switzer-
land). 15 ml of buffy coat was layered on 15 ml Ficoll Paque
Premium (GE-Healthcare, Glattbrugg, Switzerland) in 50 ml-
tubes and centrifuged for 30 min at 1500 g. The interface
containing PBMCs was transferred to new 50 ml-tubes and
washed 3 times with 50 ml ice cold PBS (resuspention and
subsequent centrifugation for 15 min at 500 g). Before the last
washing step all cells of one buffy coat were pooled. PBMCs were
frozen in 90% FCS and 10% DMSO in a concentration of 30 x
106 cells/ml and stored at –152uC. To generate osteoclasts,
PBMCs were thawed and suspended in alpha-medium (Gibco,
Invitrogen, Basel, Switzerland) containing 10% FCS, penicillin
(100 U/ml), streptomycin (100 mg/ml), human M-CSF (25 ng/
ml), human RANKL (50 ng/ml), human TGF-b (5 ng/ml) and
dexamethasone (1 mM). Cells were seeded and kept under
standard cell culture conditions for 10–12 days. Every 4 days half
of the medium was exchanged. Starting from day 9, each day
three representative wells of a 96-well plate with cells were fixed in
10% (v/v) formalin and stained using Toluidine Blue (0.1% for
1 min). Cells were inspected by light microscopy for osteoclasts
morphology (three or more nuclei and a ‘‘ruffled border’’). When
cells deemed to be differentiated sufficiently (day 11+/21) they
were subjected to osteoclast resorption assay [67].
Preparation of Primary Murine Microglia
Brains of 6 day old C57BL/6J mice were washed in 50 ml
Hanks buffered saline (HBSS) and homogenized in 1 ml HBSS.
10 ml DMEM with 10% FBS, 2 mM glutamine, penicillin
(100 U/ml) and streptomycin (100 mg/ml) (microglia-medium)
was added. Cells were collected by 10 min centrifugation at 140 g,
resuspended in 3 ml microglia-medium and seeded in poly-L-
lysine-coated cell culture flasks (coating: 0.01 mg/ml, 0.05 ml/
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cm2, 1 h, 37uC). Cells were cultured in a humidified 5% CO2
atmosphere at 37uC. After 3–4 days cells were washed in HBSS
and 5 ml fresh microglia-medium was added. After 3 more days
the medium was changed, and microglia cells were detached from
the cell culture flask by gentle tapping while astrocytes and
fibroblast stayed adherent. Microglia cells were transferred to new
poly-L-lysine-coated cell culture flasks, cultured for 3 days and
then seeded in fresh microglia-medium in a concentration of 0.5 x
106 cells/ml for experimental treatment.
Osteoclast Resorption Assay
Osteoclasts were detached from culture dishes by incubation
with Trypsin/EDTA (PAA, Co¨lbe, Germany) for 15 min at 37uC.
Cells were resuspended in fresh medium and seeded on bovine
cortical bone slices (Immunodiagnostic Systems, Frankfurt,
Germany,) in a 96-well plate (0.25 x 106/ml, 20 ml/well). Slices
were inspected by light microscopy for bone resorbtion pits from
24 h after seeding onwards. When bone resorption pits were
evident (48 h +/224 after seeding) medium was removed and new
medium with test substances (200 ml) was applied. 48–72 h later
conditioned medium was collected. Osteoclast resorbtion activity
was quantified by CrossLaps for Culture ELISA (CTX-1)
(Immunodiagnostic Systems). ELISA was performed according
to the manufacturer’s instructions. Conditioned medium was also
subjected to MMP-9 activity ELISA (see separate section).
Immunocytochemical Staining
U937-macrophages were differentiated into macrophageal cells
on glass cover slips, activated and treated as previously described.
Cells were fixed by 10 min incubation in 3.7% paraformaldehyde
and blocked by subsequent 30 min incubation in 4% donkey-
serum and 0.1% Triton X100 in PBS. After 3 washes cells were
incubated in primary antibody against MMP-9 (Abcam ab 38904)
1:100 in PBS 4% donkey-serum for 1 h at room temperature.
Subsequently, cells were incubated with secondary Antibody
(Alexa Fluor 555 donkey anti-rabbit IgG, Invitrogen) 1:500 in
PBS, 2% BSA, 0.1% Triton X100 for 1 h. In the second half hour
phalloidin coupled to Alexa 488-dye (molecular probes) was added
1:40 in order to stain the actin-cytoskelleton. Nuclei were stained
by 5 min incubation in DAPI (Invitrogen) 1:1000 in PBS. After 3
washes cells were mounted in prolong gold-mounting medium
(molecular probes), and analyzed by fluorescent microscopy using
the software ‘‘Application Suite 2.3.0 Advanced Fluorescence’’
(Leica).
Cell Viability
The integrity of cell membranes was assessed by microscopic
trypan blue exclusion technique viability was measured by MTT
assay. U937-macrophages were differentiated in 96-well cell
culture plates (2, 4, and 8 x 104 cells/well) and treated with 2 or
4 mM WIN (or DMSO as vehicle control) for 24 h. Cells were
supplied with 0.5 mg/ml MTT-tetrazolium-salt (3-(4,5-Di-
methylthiazol-2-yl)-2,5-diphenyltetrazolium-bromide) and incu-
bated for 3 h. Cell lysis was induced by adding 50 ml lysis-buffer
(20% SDS, 50% N,N-dimethylformamid) per well and incubation
at 37uC overnight. Absorption at 562 nm was measured and
reductase enzyme activity was calculated as percentage of control
after subtraction of blanks.
MMP-9 Activity ELISA of Conditioned Medium
MMP-9 activity in conditioned medium of U937-macrophages,
primary human macrophages and osteoclastic cells was quantified
by the ELISA Kit Fluorokine E human Active MMP-9 (R&D
Systems) according to the manufacturer’s instructions. All samples
were diluted 1:100 and 4-aminophenylmercuric acetate (APMA)
was added to detect all potentially active MMP-9. Samples were
measured in triplicates.
Quantification of MMP-9 Protein in Conditioned Medium
and BALF (Bronchoalveolar Lavage Fluid)
Conditioned medium of primary murine microglia and BALF
were subjected to MMP-9 ELSA Kit Quantikine Mouse MMP-9
(R&D Systems) according to the manufacturer’s instructions. All
samples were diluted 1:2 and measured in triplicates.
Western Blots Analyses
After exposure to the experimental conditions, U937-macro-
phages or primary human macrophages were scraped from the cell
culture flasks and washed in ice cold PBS. Cells were suspended in
lysis buffer (4 M urea, 0.5% sodium dodecyl sulfate (SDS),
62.4 mM tris(hydroxymethyl)aminomethane (Tris) pH 6.8,
10 ml/ml protease-Inhibitor-cocktail Set III (Calbiochem) and
1 mM phenylmethanesulfonylfluoride (PMSF)), incubated for 1 h
on ice. Cells were sonified by 10 pulses, 1 second per pulse. Protein
concentrations were measured using the BCA TM Protein Assay-
Kit (Thermoscientific, Rockford, IL, USA). Cell culture superna-
tants were collected and concentrated 10-fold by vacuum
centrifugation. Equal amounts of protein (15–30 mg) or 30 ml of
concentrated conditioned medium were mixed with 4 x loading
buffer (0.5 M Tris pH 6.8, 20% SDS, 50 mM sodium ethylene-
diaminetetraacetic acid (NaEDTA), 0.2% bromphenolblue, 10%
Glycerol, 20% b-mercapthoethanol), denatured for 5 min at 95uC,
and loaded on 8% SDS-gels (Separating gel: 466 mM Tris base
pH 8.8, 8% polyacrylamid, 0.2% SDS, 0.75% ammonium
persulfate (APS), 0.08% tetramethylethylenediamine (TEMED).
Stacking gel: 466 mM Tris base pH 6.8, 5% polyacrylamide,
0.1% SDS, 0.75% APS, 0.08% TEMED). Elecrophoresis was
carried out in 25 mM Tris base, 192 mM glycin, 0.1% SDS at
120 V. Subsequently, proteins were blotted onto cellulose nitrate
membranes (Pierce, Thermo Fisher Scientific, Rockford, IL, USA)
in transfer buffer (25 mM Tris base, 192 mM glycin, 20%
methanol (v/v)). Membranes were rinsed in washing buffer
(10 mM Tris, 150 mM NaCl, 0.05% tween) and blocked for 1 h
in blocking buffer (washing buffer with 5% skimmed milk).
Primary antibodies were diluted in blocking buffer and incubated
overnight at 4uC or 3 h at room temperature. If not stated
differently, MMP-9 was detected with mouse monoclonal anti-
MMP-9 antibody (IM37L, Calbiochem, diluted 1:2000 in washing
buffer +5% BSA) that recognizes the aminoterminal end of MMP-
9 or, when indicated, by a goat polyclonal antibody (sc-6840,
Santa Cruz, diluted 1:2000 in washing buffer +5% BSA) that
recognizes the c-terminal end. Extracellular regulated kinase
(ERK1/2) and phosphorylated ERK1/2 were recognized by
rabbit polyclonal antibodies (9102 and 9101, Cell signaling,
Boston, MA, USA, diluted 1:1000 in washing buffer +5% BSA). B-
actin was detected with mouse Monoclonal Anti-b-Actin antibody
(A544.1, Sigma, diluted 1:10000 in blocking buffer). Membranes
were washed and incubated at room temperature for 2 h with
secondary antibodies (Odyssey: donkey anti-mouse IgG IRDye
680 (926–32222), donkey anti-mouse IgG IRDye 800 (926–
32213), goat anti-rabbit IgG IRDye 680 (926–32221), goat anti-
rabbit IgG IRDye 800 (926–32211), donkey anti-goat IgG IRDye
680 (926–32223), diluted 1:10000 in blocking buffer). Membranes
were washed three times and pictures were taken using OdysseyH
Infrared Imaging System (LI-COR). Sizes of bands were estimated
by comparison with a prestained molecular weight marker
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(Fermentas, Le Mont-sur-Lausanne, Switzerland) run on the same
gel.
Zymography
Gelatinolytic activity of MMP-9 in the conditioned medium
was assessed by zymography. U937-macrophages and primary
human macrophages were treated with WIN (or DMSO as
vehicle control) for 24 h and conditioned medium was collected.
Cells were removed by centrifugation at 500 g for 5 min. 8 ml
of conditioned medium was mixed with non-reducing loading-
buffer (0.5 M Tris pH 6.8, 20% SDS, 50 mM NaEDTA, 0.2%
bromphenolblue, 10% glycerol) and loaded onto an 8% SDS-
polyacrylamide gel (see SDS-PAGE) additionally containing
0.1% gelatine. Electrophoresis was performed as described.
Renaturation was achieved by incubation in 50 mM Tris
pH 7.4, 5 mM CaCl2, 1 mM ZnCl2, 2.5% Triton X100 for
30 min. Gelatinolytic bands were developed through incubation
in 50 mM Tris pH 7.4, 5 mM CaCl2, 1 mM ZnCl2 for 24–48 h
and subsequent staining with 0.5% Coomassie G250, 30%
EtOH, 10% acetic acid and destaining with 30% ethanol, 10%
acetic acid. Sizes of the clear bands were estimated by
comparison with a prestained molecular weight marker
(Fermentas) run on the same gel.
Glycosidase Digestion
Cell lysates were prepared as described in the section Western blot
analyses. Endoglycosidase H digestion: 10 mg protein were mixed
with 80 ml Endoglycosidase H incubation buffer (1% Nonidet P-
40, 25 mM EDTA, 50 mM Na-acetate, pH 5.5). Subsequently
0.4 ml b-mercapthoethanol was added, followed by denaturation
at 95uC for 5 min. After addition of 1 ml PMSF, 0.5 ml proteinase
inhibitor cocktail Set III and 1 ml (20 mU) endoglycosidase H
(ROCHE, Mannheim, Germany), digestion took place at 37uC
overnight. N-Glycosidase F digestion: 10 mg protein were mixed
with 80 ml 25 mM Na-phosphat pH 7.5. Afterwards 0.2 ml b-
mercapthoethanol was added, followed by denaturation at 95uC
for 5 min. After addition of 1 ml proteinase inhibitor cocktail Set
III, 0.45ml NP-40 and 4 ml (4 U) N-Glycosidase F (ROCHE)
digestion took place at 37uC overnight. The samples were then
subjected to SDS-PAGE.
Quantitative Real-time Polymerase Chain Reaction (PCR)
Analysis
Total RNA from U937-macrophages was isolated using Trizol
reagent (Invitrogen, Basel, Switzerland) according to the manu-
facturer’s instructions and stored at 280uC. For cDNA-synthesis
1 mg of total RNA was transcribed with Reverse Transcription
System-Kit (Promega, Wallisellen, Switzerland) using random
hexameres. Quantification of mRNA levels of MMP-9 was
achieved by quantitative real-time polymerase chain reaction
using QuantiTect Primer Assay (QT00040040, Qiagen, Hilden,
Germany) according to the manufacturers instructions. PCR
reactions were run on a LightCyclerH (Roche Applied Science)
and mRNA level was calculated using delta-delta-CP-method with
glycerinaldehyd-3-phosphat-dehydrogenase (GAPDH) as a refer-
ence gene (Qiagen, QT01192646) and control samples (treatment
with only vehicle) as calibrator for calculation.
Statistical Analysis
The comparison between two groups was performed with a t-
test, while comparison between three or more groups was realised
by analysis of variance and subsequent Newman-Keuls Multiple
Comparison test. The analyses were carried out with the software
‘‘GraphPad Prism 3.0’’, p,0.05 was considered statistically
significant.
Results
WIN Treatment Decreased the Secretion and Activity of
Matrix Metalloproteinase-9 in Inflammatory U937-
macrophages
As activated macrophages are a major source of MMP-9 in
inflamed tissue, we first used PMA-differentiated and LPS-
activated human U937 cells (U937-macrophages) as a model
system. In this well-established model, PMA-differentiation leads
to morphological and functional convergence to a macrophage-
like phenotype, including a smooth surface, extended pseudopo-
dia, cell cycle arrest and adherence to surfaces. Upon inflamma-
tory stimulation with LPS, cells secrete pro-inflammatory medi-
ators typical for activated macrophages, such as TNF-a, IL-1-b
[61,62], IL-6 [68] and the matrix metalloproteinases MMP-1,
MMP-9 [69] and MMP-12 [70]. U937-macrophages were treated
with 2 or 4 mM of WIN for 24 h. Subsequently, Western blot
analysis was performed using antibodies against MMP-9. WIN
treatment induced a decrease of secreted MMP-9 upon treatment
with 2 mM, and an even stronger decrease upon treatment with
4 mM of WIN (fig. 1a). To investigate the specificity of WIN-
induced inhibition of MMP-9 secretion, we also analyzed the
secretion of MMP-12, the second most prominently expressed
MMP in macrophages [71]. In contrast to MMP-9, the secretion
of MMP-12 was not altered by WIN-treatment, which demon-
strated that WIN does not generally inhibit MMP secretion. As the
amount of MMP-9 protein was decreased, we investigated if this
decrease is also valid at the level of activity. For this purpose,
activity-ELISA and MMP-9 zymography were applied. The
activity-ELISA displayed a strong down-regulation of MMP-9
activity to 42% (+/220, n= 3) and 18% (+/28, n= 3) of control,
by 2 and 4 mM WIN respectively (fig. 1b). Accordingly,
zymography demonstrated a decreased gelatinolytic activity after
treatment with 2 and 4 mM WIN respectively (fig. 1c). To rule out
toxicity of WIN, cell number, percentage of viable cells, and
metabolic activity of U937-macrophages after WIN-stimulation
were assessed. According to trypan blue staining, cell number and
percentage of viable cell were not significantly altered by WIN-
treatment. MTT-reduction was decreased to 94% (+/213, n= 3)
and 77% (+/26, n= 3) upon 2 mM and 4 mM WIN respectively.
In summary the data provides evidence, that WIN is not toxic on
U937-macrophages in the applied concentrations. The observed
MMP-9-bands of 92 kDa in Western blot analyses and zymo-
graphy represent the latent form of MMP-9 which still contains
the pro-sequence. Proteolytically activated MMP-9 (ca. 85 kDa)
was not observed in our studies. This is in line with previous
reports showing a presence of 92 kDa MMP-9 and an absence of
the activated 85 kDa form and attributed to rapid dilution of
MMP-9 and its potential activators in cell culture systems [72]. All
in all, WIN-treatment specifically downregulated MMP-9 secre-
tion and activity in inflammatory macrophageal cells.
Inhibition of MMP-9 Secretion by WIN was Associated
with an Intracellular Accumulation of Mature 92 kDa-
MMP-9
Based on the observation that WIN strongly inhibited MMP-9-
secretion in macrophages, we then investigated if MMP-9
biosynthesis was affected by WIN. We thus analysed MMP-9 in
cell lysates of U937-macrophages after WIN-treatment with
Western blot. Whereas we expected reduced amounts of
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intracellular MMP-9 upon WIN-treatment, surprisingly, the
amount of intracellular MMP-9 was strongly enhanced (fig. 2a).
Associated with the intracellular accumulation of MMP-9, we
observed a band shift from 85 kDa to 92 kDa after WIN-
treatment (fig. 2a). In a kinetic analysis of MMP-9 in WIN-treated
macrophages, the intracellular 85 kDa-MMP-9 disappeared com-
pletely within 24 h, whereas the 92 kDa-MMP-9 appeared after
30 min as a weak band that increased with time (fig. 2b). 85 kDa is
the size of MMP-9 that is usually described in cell lysates of U937
and other cells, it represents an immature form which is not yet
fully glycosylated [73,74]. 92 kDa is the size of fully glycosylated
mature MMP-9 which is commonly found in conditioned medium
[33], as also seen in our study (compare fig. 2a and fig. 2b).
Because the 92 kDa-MMP-9 form in cell lysates appeared
simultaneously to decreased secretion of MMP-9, we assumed
that the MMP-9 secretion process was inhibited. This contributed
to an intracellular accumulation of fully glycosylated mature
MMP-9 inside the cells. To figure out whether the WIN-induced
intracellular 92 kDa-MMP-9 form is indeed a mature form of
MMP-9 (and therefore higher glycosylated than the 85-kDa
MMP-9 form), we examined the glycosylation status of the
intracellular 85 kDa and 92 kDa forms by means of Endoglyco-
sidase H- and N-glycosidase F-digestion. Endoglycosidase-H does
not affect fully glycosylated complex oligosaccharides, but
specifically cleaves core oligosaccharide chains of the high-
mannose and hybrid type [75]. For this reason endoglycosidase-
H is a useful tool to distinguish fully glycosylated mature proteins
from those holding unprocessed oligosaccharide chains. As
demonstrated in fig. 3a, lanes 1 and 2, the intracellular 85 kDa-
MMP-9 in the non-treated macrophages was endoglycosidase H-
sensitive and had a size of 80 kDa after digestion. In contrast, the
intracellular 92 kDa-MMP-9 from the WIN-treated macrophages
was endoglycosidase H-resistant, this is consistent with the
addition of complex carbohydrates (fig. 3a, lanes 3 and 4). We
consequently investigated whether the size differences between the
intracellular 85 kDa-MMP-9 and 92 kDa-MMP-9 was due to N-
linked glycosylation. Both forms of MMP-9 were exposed to
digestion by N-glycosidase F, which removes all N-linked
oligosaccharide chains. Upon digestion, both MMP-9 forms lost
5 kDa of size (fig. 3b, lines 1–4). Taken together, the resistance of
the intracellular 92 kDa-MMP-9 after WIN-treatment against
endoglycosidase H digestion and the sensitivity of MMP-9 from
untreated and WIN-treated macrophages against N-glycosidase F
digestion suggest that the MMP-9 which accumulated after WIN-
treatment was mature N-glycosylated MMP-9. Interestingly, the
endogenous cannabinoids 2-Arachidonoylglycerol (2-AG) and N-
arachidonoylethanolamide (Anandamid) (concentrations from
5 nM until 5 mM) did not induce an inhibition of secretion or
an intracellular accumulation of MMP-9 (data not shown).
WIN-treatment did not Alter Intracellular Distribution of
MMP-9 in U937-macrophages
The accumulation of 92 kDa-MMP-9 seen by Western Blot
analysis raised questions about the cellular localization of
accumulated MMP-9. We investigated MMP-9 localization with
immunocytochemical staining. The results are demonstrated in
fig. 4, which shows that intracellular MMP-9 was localized in
vesicles throughout the cytoplasm (fig. 4a and b) and in the
perinuclear region (fig. 4a and c). However, WIN treatment did
neither change the intracellular distribution pattern nor the
amount of highly MMP-9 expressing cells (6.8% +/20.6, n= 3,
without WIN and 6.2% +/20.9, n= 3, after WIN treatment).
MMP-9 located at the surface of the cells was observed in neither
of the cell types. The same samples were used for Western Blot
analysis utilizing the same MMP-9 antibody as for the immuno-
cytochemical staining, showing intracellular accumulation of a
92 kDa-MMP-9 as seen in the previous experiments (fig. 4d).
Thus, immunocytochemical localization of M MP-9 revealed no
changes in the intracellular distribution pattern of MMP-9 caused
by WIN-treatment.
Inhibited Secretion and Intracellular Accumulation of
MMP-9 was Mediated by a Specific Binding Site Different
from Classic Cannabinoid-receptors
In a next step we examined which receptor or binding site was
responsible for the inhibition of the secretion and the increase of
intracellular accumulation of MMP-9. For this we first tested if
these effects are dependent on specific WIN binding or not, e.g. as
an unspecific physical effect. Non-site-specific or physical effects
Figure 1. Treatment with WIN reduced secretion and activity of
MMP-9 in macrophageal differentiated U937 cells. (a) Western
blot analysis of conditioned medium using antibodies against MMP-9
and MMP-12. WIN-treatment resulted in a significant decrease of
secreted MMP-9, whereas MMP-12 secretion was not affected. Control
cells were treated with vehicle. The figure shows one representative
analysis out of three. (b) MMP-9 activity-ELISA of conditioned medium.
Upon treatment with 2 mM WIN a reduction of MMP-9 activity was
observed, after treatment with 4 mM WIN the reduction was even
stronger. Control cells were treated with vehicle. Data are shown as
means +/2 SD, n= 3. *p,0.05 vs. control, **p,0.01 according to
Newman-Keuls Multiple Comparison test following ANOVA. (c) Zymo-
graphy of conditioned medium. Gelatinolytic activity was strongly
decreased by 2 and 4 mM WIN. The figure shows one representative
analysis out of three.
doi:10.1371/journal.pone.0048272.g001
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such as changes in membrane fluidity should also be induced by a
stereo-enantiomer of WIN. A stereo-enantiomer exhibits the same
physical and chemical properties, but another steric specificity. For
this reason we treated U937-macrophages with S(–)-[2,3-Dihydro-
5-methyl-3-[(4-morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzox-
azinyl]-1-naphthal-enyl)methanone mesylat (WIN3), which is a
Figure 2. Inhibition of MMP-9 secretion was accompanied by an intracellular accumulation of a 92 kDa-MMP-9. Western blot analysis
of cell lysates (MMP-9 cellular) and conditioned medium (MMP-9 secreted) of U937-macrophages treated with WIN using anti-MMP-9 antibody.
Control cells were treated with vehicle. (a) Upon 24 h treatment with WIN, the amount of MMP-9 in the cell lysate increased, whereas the amount of
secreted MMP-9 in the conditioned medium decreased. The size of MMP-9 in the cell lysate shifted from 85 kDa to 92 kDa. Control cells were treated
with vehicle. The figure shows one representative analysis out of three. (b) Kinetic analysis of MMP-9 after WIN-treatment throughout 24 h. The
inhibition of MMP-9 secretion was accompanied by an accumulation of intracellular 92 kDa-MMP-9. The intracellular 85 kDa-MMP-9 disappeared with
time. The figure shows one representative analysis out of three.
doi:10.1371/journal.pone.0048272.g002
Figure 3. Glycosylation of intracellular 92 kDa-MMP-9 after WIN-treatment was different from the 85 kDa-MMP-9 in untreated
U937-macrophages. The pictures show one representative analysis out of three. (a) Western blot analysis using anti-MMP-9 antibody of
endoglycosidase H-digested cell lysates treated with or without WIN. The WIN-induced 92 kDa-MMP-9 was resistant to digestion, whereas the
85 kDa-MMP-9 from control cells loses 5 kDa upon digestion. (b) Digestion with N-glycosidase F resulted in a loss of 5 kDa in both MMP-9 forms.
doi:10.1371/journal.pone.0048272.g003
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receptor-inactive enantiomer of WIN. As demonstrated in fig. 5a,
4 mM WIN3 was not able to reduce MMP-9 secretion, to induce
an intracellular band shift or to lead to accumulation of MMP-9.
This was also the case when WIN3 was used in much higher
concentrations (10 or 25 mM). The data clearly indicates that WIN
regulates MMP-9 secretion via a specific stereo-selective binding
site.
To study whether this specific binding site is one of the
classical cannabinoid receptors CB1 or CB2, these receptors
were inhibited pharmacologically with AM251 and AM630,
respectively. Surprisingly, inhibition of the receptors did not
abolish or attenuate the inhibited secretion or the band shift
and the intracellular accumulation of MMP-9 (fig. 5b). The CB-
inhibitors alone did not have any effect. To investigate the
involvement of G protein coupled receptors, we performed
experiments with different concentrations of pertussis toxin. We
found that the WIN-induced MMP-9 regulation was pertussis
toxin-insensitive (fig. 5c). Another receptor which has shown to
bind the cannabinoid ligands ajulemic acid and 2-Arachido-
noylglycerol (2-AG) is the peroxisome proliferator-activated
receptor-c (PPARc) [76]. This receptor belongs to the ‘‘nuclear
hormone receptor family of ligand-dependent transcription
factors’’ and it mediates signals in adipocyte-differentiation,
glucose-metabolism, and immune regulation [77]. Experiments
with 2-chloro-5-nitrobenzanilide (GW9662), a potent PPARc
antagonist, demonstrated that WIN-induced inhibition of
secretion and intracellular accumulation of MMP-9 was
independent of PPARc (fig. 5d).
WIN-induced Intracellular Accumulation and Inhibition of
MMP-9 Secretion was Mimicked by the TRPV1 Inhibitor
Capsazepine and Antagonized by the TRPV1 Agonist
Capsaicin
In the search for the functional WIN-binding site we
subsequently wanted to assess a possible involvement of TRPV1
in the WIN-induced inhibition and intracellular accumulation of
MMP-9. TRPV1 has been shown to mediate WIN-induced effects
in neuronal and immunological functions [78,79]. For this reason,
we performed experiments using pharmacological inhibition and
stimulation of TRPV1. Inhibition of TRPV1 by capsazepine
(CZP) enforced a similar band shift of MMP-9 as the incubation
with WIN (fig. 6a), whereas we could not detect an additive effect
of WIN and CZP. Activation of TRPV1 by the agonist capsaicin
(CIC) resulted in a partial antagonisation of the WIN-induced
band shift of MMP-9 (fig. 6b). Measurement of MMP-9 activity in
the conditioned medium revealed that CZP enhanced the WIN-
induced downregulation of MMP-9 secretion, whereas CIC
reduced ameliorated this effect (fig. 6c). CZP significantly
increased the decline of MMP-9-activity after WIN treatment
from 55% (+/28, n= 3) to 34% (+/26, n= 3) compared to
control cells, whereas CIC antagonized the WIN-induced effect
and reduced the decline of MMP-9-activity significantly from 55%
(+/28, n = 3) to 75% (+/29, n= 3) (fig. 6c). Thus, ion channel
TRPV1 represents a possible binding site of WIN by which MMP-
9 secretion is inhibited and intracellular accumulation is promot-
ed.
Intracellular Accumulation of MMP-9 was not Mediated
via Rho Signaling
In a next step we looked for a possible mechanism by which
WIN might exert its inhibiting effect on MMP-9 secretion. It has
been demonstrated that Rho/ROCK signaling is involved in the
regulation of MMP-9 secretion [80,81,82]. We incubated U937-
macrophages with the Rho-inhibitor Y27632 to assess if Rho
signaling is essential for the secretion of MMP-9 in our model
system. We detected a slight decrease of MMP-9 secretion by
Y27632, but no effect on intracellular MMP-9 accumulation (data
not shown). We reckon that Rho signaling may contribute to the
regulation of MMP-9 secretion in our model system, but via
different mechanisms than the WIN-induced intracellular accu-
mulation of MMP-9.
Transcriptional Regulation of MMP-9 upon WIN
Treatment Involved ERK-Phosphorylation
In the following we investigated if transcriptional regulation
plays a role in intracellular MMP-9 protein accumulation upon
WIN treatment. We performed quantitative real-time measure-
ments of MMP-9 mRNA expression. As demonstrated in fig. 7a,
MMP-9 mRNA was downregulated to a ratio of 0.653, (+/
20.085, n= 3) and 0.517, (+/20.037, n = 3) by 2 mM WIN and
4 mM WIN compared to the control sample. Because downreg-
ulation of MMP-9 mRNA expression was associated with
intracellular accumulation of MMP-9 protein, we assumed a
negative feedback effect of MMP-9 protein on MMP-9 mRNA
expression. Thus, we compared the kinetics of MMP-9 mRNA
down-regulation with the down-regulation of MMP-9 protein
secretion (fig. 7b). Levels of mRNA and secreted MMP-9 protein
are given as percentage of the amounts that were measured in
untreated cells at the corresponding time points. In fig. 7b it is
demonstrated that MMP-9 mRNA expression level after 1 h
WIN-treatment was 106% (+/213.6, n= 3) and decreased
afterwards to 56% (+/23.0, n= 3) within 24 h. In contrast, the
level of secreted protein after 1 h was already decreased to 36%
(+/215, n= 3) compared to the appropriate controls, and the
degree of down-regulated secretion did not changed much during
24 h (37% (+/217, n= 3) after 6 h, 43% (+/226, n= 3) after
12 h, 22% (+/212, n = 3) after 24 h). Thus, mRNA down-
regulation occurred with a time delay compared to downregula-
tion of MMP-9 secretion, suggesting a negative feedback
mechanism on MMP-9 mRNA expression by the disturbed
secretion and drastic intracellular accumulation (see fig. 2 and
fig. 3).
Recently it has been shown that dephosphorylation of ERK1/2
leads to an inhibition of MMP-9 transcription [35,83]. We
investigated the hypothesis that the phosphorylation status of
ERK1/2 could be involved in the observed WIN-induced
reduction of MMP-9 mRNA. As demonstrated in fig. 8, column
1 and 2, 4 mM WIN contributed to a profound dephosphorylation
of ERK1/2 accompanying the inhibition of MMP-9 secretion,
intracellular MMP-9 protein accumulation and a decrease of
MMP-9 mRNA. To investigate if dephosphorylation of ERK1/2
was responsible for down regulation of MMP-9 mRNA in our
system, we performed experiments using the ERK1/2-phosphor-
Figure 4. WIN did not alter the intracellular localization of MMP-9. Immunocytochemical staining of MMP-9 (red), F-actin (green) and nuclei
(blue) of U937-macrophages which were treated for 24 h with 4 mM WIN or DMSO (control). The figure shows one representative analysis out of five.
(a) Two types of MMP-9 expressing cells are observed in control cells and in WIN-treated cells, cells with a low MMP-9-signal in a vesicular pattern
(¤), and cell with a brighter signal near the nucleus (&). (b) Magnification of the cell type with MMP-9 in vesicular distribution. (c) Magnification of
the cells type with perinuclear MMP-9-distribution. (d) Western blot analysis of the same samples using the same MMP-9 antibody as for
immunocytochemistry (Abcam ab38904).
doi:10.1371/journal.pone.0048272.g004
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ylation inhibitor U-0126. As demonstrated in fig. 8, column 3,
dephosphorylation diminished the amount of MMP-9 mRNA to
37% (+/26, n = 3), which was a significantly lower than after
WIN-treatment alone, which down-regulated MMP-9 mRNA to
55% (+/25, n = 3). Parallel treatment with U-0126 and WIN
caused a non-significant further decrease of MMP-9 mRNA to
32% (+/29, n= 3) (P=0.17). Dephosphorylation of ERK1/2 by
U-0126 was associated with a slight reduction of MMP-9
secretion, but no intracellular accumulation of MMP-9 protein
was detected (fig. 8, column 4). To sum up, ERK1/2 was
dephosphorylated by WIN treatment and pharmacological inhi-
bition of ERK1/2 phosphorylation decreased MMP-9 mRNA
expression, but did not affect MMP-9 maturation. For this reason
we suggest that ERK1/2 phosphorylation participated primarily
in MMP-9 mRNA down-regulation, but secondary to intracellular
accumulation of MMP-9 protein.
Inhibited Secretion and Intracellular Accumulation of
MMP-9 in WIN-treated Inflammatory Primary Human
Monocytes
To investigate whether the WIN-induced effect on MMP-9
regulation is also present in primary human cells of the monocyte-
macrophages system, we performed the key experiments in LPS-
Figure 5. WIN-induced regulation of MMP-9 was mediated by a specific binding site, which is different from CB1, CB2, and PPARy,
and independent from pertussis-toxin. Western blot analysis of cell lysates (MMP-9 cellular) and conditioned medium (MMP-9 secreted) of
U937-macrophages treated with the receptor-inactive WIN-enantiomer S(–)-[2,3-Dihydro-5-methyl-3-[(4-morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-
benzoxazinyl]-(1 naphthalenyl) methanone mesylat (WIN3), specific inhibitors for cannabinoid-receptors or pertussis toxin (PTX). Control cells were
treated with vehicle. In each case the figure shows one representative analysis out of three. (a) Treatment with WIN3 demonstrated the specificity of
the effect of WIN. (b) Inhibitors for CB1 (AM251) and CB2 (AM630) did not abolish the WIN-induced inhibition of secretion and intracellular
accumulation of MMP-9. (c) Treatment with PTX did not abolish the WIN-induced effect. (d) Inhibition of PPARy with GW9662 had no influence on the
effect of WIN on MMP-9.
doi:10.1371/journal.pone.0048272.g005
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stimulated primary peripheral monocytes isolated from human
blood. Western blot analyses of conditioned medium and cell
lysates revealed that WIN inhibited MMP-9 secretion and induced
a band shift of the intracellular MMP-9 protein from 85 kDa to
92 kDa as observed in U937-macrophages (fig. 9a). MMP-9
activity-ELISA demonstrated that MMP-9 activity in the condi-
tioned medium was reduced significantly by 4 mM WIN to 28%
(+/29, n= 3), whereas 2 mM WIN had no significant effect
(fig. 9b). Accordingly, a decreased gelatinolytic activity after
treatment with 4 mM WIN was observed in zymography (fig. 9c).
Therefore, inhibited secretion and intracellular accumulation of
92 kDa-MMP-9 was also present in WIN-treated inflammatory
primary human monocytes.
WIN-induced MMP-9 Regulation in Human Primary
Osteoclasts, but not in Primary Murine Microglia Cells
After we identified the regulation of MMP-9 maturation and
secretion by a WIN-sensitive site in a macrophageal differentiated
human cell line (U937-macrophages) and in primary human
monocytes, there is a possibility that this regulatory principle is
also present in other cell types of the monocyte-macrophage
system. For this reason we also studied the effect on the bone- and
brain-resident macrophages, osteoclasts and microglial cells. As
demonstrated in fig. 10a, WIN induced an accumulation of
intracellular 92 kDa-MMP-9 and a decrease of the secreted
MMP-9 in osteoclasts as it was observed in macrophageal
differentiated U937- and primary macrophageal cells. Secreted
MMP-9-activity was reduced significantly to 61% (+/229, n= 4)
upon WIN-treatment. In contrast we did not detect a clear MMP-
Figure 6. TRPV1 was involved in inhibition of secretion and intracellular accumulation of MMP-9 upon WIN-treatment. (a,b) Western
blot analyses of U937-macrophage cell lysates (MMP-9 cellular) using MMP-9 antibody. (a) Treatment with the TRPV1 antagonist capsazepine (CZP)
enhanced the WIN-induced size shift of MMP-9 from 85 to 92 kDa when given parallel to WIN and mimicked this effect when administered separately.
The figure shows one representative analysis out of three. (b) Treatment with the TRPV1 agonist capsaicin (CIC) antagonized the WIN-induced size
shift while it exhibited no effect when given alone. The figure shows one representative analysis out of three. (c) MMP-9 activity–ELISA of conditioned
medium. The WIN-induced decrease of MMP-9 activity was intensified by CZP (10 mM), and antagonized by CIC (10mM). Data are shown as means +/2
SD, n = 3. **p,0.001 *p,0.1 according to Newman-Keuls Multiple Comparison test following ANOVA.
doi:10.1371/journal.pone.0048272.g006
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9 band in Western blot-analysis of primary murine microglia cells.
There was no change in size or quantity after treatment with WIN.
Quantification of secreted MMP-9 by ELISA revealed no
significant changes upon WIN-treatment in primary microglial
cells (fig. 10b).
Bone Resorption Activity of Osteoclastic Cells was
Decreased Upon WIN-treatment and Dependent on
TRPV1
After detecting WIN-sensitive MMP-9 maturation and secretion
in primary osteoclasts, and after establishing that MMP-9 is a key
protein in osteoclast activity and bone resorption [39,41], we
observed if WIN-treatment was capable of reducing bone
resorption by osteoclasts. We performed an in vivo-like bone
resorption assay (Crosslaps-ELISA) as a model system to estimate
the functional relevance of the WIN-induced inhibition of MMP-
9. According to our hypothesis, quantification of bone resorption
activity revealed that WIN-treatment resulted in a significant
down-regulation of bone resorption to 71% (+/219, n= 5)
compared to control cells (vehicle treated). In the following, we
tested the possibility that the decreased MMP-9 secretion and
subsequent reduction of bone resorption by osteoclasts were based
on TRPV1 activation, as revealed for U937-macrophages (see
fig. 6). As demonstrated in fig. 11, reduced bone resorption and
MMP-9 secretion after WIN treatment were antagonized by the
TRPV1 agonist capsaicin (CIC). The reduced bone resorption was
reversed ameliorated significantly from 71% (+/219, n = 5) to
96% (+/214, n = 5) (fig. 11a), and the reduced MMP-9 activity in
conditioned medium was restored from 61% (+/229, n= 4) to
93% (+/28, n= 4) (fig. 11b).
The synthetic Cannabinoid WIN 55,212 2 (WIN)
Decreased the Amount of MMP-9 Secreted by White
Blood Cells in Bronchoalveolar Lavage Fluid (BALF) in a
Murine Model of Smoke-induced Lung Inflammation
To look into wheather the in vitro observed suppressive effect of
WIN on MMP-9 secretion is also valid in vivo, we applied a murine
model of cigarette smoke-induced lung inflammation. Lung
inflammation was achieved by cigarette-smoke-exposure over 4
days (control animals received air instead of smoke), and the mice
were treated with WIN (5 mg/kg, i.p.) or vehicle daily. MMP-9
was then measured in bronchoalveolar lavage fluid (BALF) with
ELISA. As the main source for MMP-9 and as an indicator for the
strength of inflammation white blood cells (WBC) were quantified
in BALF. In the BALF of animals that received air a total amount
of 0.07 ng (+/20.13 n= 7) MMP-9 was measured, whereas
animals with smoke-induced lung inflammation had a content of
6.36 ng (+/21.68, n= 8). I.p. injection of WIN led to a decrease of
MMP-9 in BALF to 3.94 ng (+/21.90, n= 9) (fig. 12a). The total
number of WBCs in BALF was increased by smoke-exposure from
1.321 x 105 (+/20.26 n= 7) in the air-treated group to 2.980 x
105 (+/20.601, n = 8) in the smoke-group. I.p. WIN-treatment did
not alter the amount of WBCs significantly (2.812 x 105 (+/
20.334, n= 9)) (fig. 12b). Nevertheless, to rule out the possibility
that the decrease in MMP-9 was due to changes in WBC cell
number, the amount of MMP-9 was calculated as ratio between
MMP-9 and WBCs. This ratio decreased significantly from
2.25 ng/105 WBCs (+/20.2782, n= 8) to 1.40 ng/105 WBCs
(+/20.2168 n= 9) as a consequence of WIN treatment (fig. 12c).
Thus, administration of the cannabinoid receptor agonist WIN
was capable of inhibiting MMP-9 release in vivo in a mouse model
of lung inflammation.
Taken together, we demonstrated that binding of the canna-
binoid-receptor agonist WIN to a stereo-selective, specific binding
site in cells of the monocyte-macrophage-system induced a
significant disturbance of MMP-9 processing and secretion, which
subsequently down-regulated MMP-9 mRNA expression. This
downregulation probably occurred via ERK1/2-phosphorylation-
dependent pathway. We suppose an involvement of TRPV1, but
other still unidentified sites present further possibilities. Downreg-
ulation of MMP-9 activity was demonstrated in lung inflammation
in an in vivo murine model and in in-vivo-like bone tissue cultures
with active osteoclasts. They are examples of possible functional
consequences of MMP-9 downregulation within the monocyte-
macrophage-system.
Discussion
The collagenase MMP-9 constitutes a crucial element of
inflammation and it is causally involved in severe tissue destruction
during inflammatory conditions including inflammatory bowel
disease [47], vascular disease [46], lupus erythematosus, Sjo¨gren’s
syndrome, sclerodermia, polymyositis, multiple sclerosis [48] and
COPD [84]. Therefore, inhibition of MMP-9 secretion or activity
is considered a promising therapeutic target during inflammatory
diseases. Many inhibitors have been developed and they have been
tested in vivo [26,29]. In our study, we present evidences that
MMP-9 maturation and secretion can be drastically mitigated by
Figure 7. WIN down-regulated MMP-9 mRNA in U937-macro-
phages. (a) Quantitative real-time PCR of MMP-9 mRNA. 2 mM and
4 mM WIN decreased MMP-9 mRNA to 66% and 55% respectively. Data
are shown as means +/2 SD n=3. **p,0.01 vs. control according to
Newman-Keuls Multiple Comparison test following ANOVA. (b)
Comparison of MMP-9 mRNA and secreted protein, assessed by real-
time PCR (n = 3) and densitometry of Western blot analyses (n = 2).
Values of mRNA and secreted MMP-9 Protein are given as percentage of
the amounts that were measured in untreated cells at the correspond-
ing time point. Secretion of MMP-9 protein was already decreased to
40% after 1 h, and remained in this range for 24 h. In contrast, no
mRNA decrease was observed after 1 h, mRNA level decreased steadily
to 55% after 24 h. Data are shown as means +/2 SD, *p,0.05, **p,0.01
vs. 1 h according to Newman-Keuls Multiple Comparison test following
ANOVA.
doi:10.1371/journal.pone.0048272.g007
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the cannabinoid receptor agonist WIN55,212-2. We further
suggest that this anti-inflammatory action is mediated by TRPV1
receptors. Finally, we found that the cannabinoid receptor agonist
WIN55,212-2 represents a potent tissue protective drug which
reduced MMP-9 activity in lung inflammation in vivo and
osteoclast-mediated bone destruction in an in vivo-like model
system.
Anti-inflammatory properties of WIN have been described in
previous in vivo studies: Berdyshev et al. found that intranasal
application of WIN reduced TNF-a concentration in BALF in a
mouse model of LPS-induced inflammation [85]. In an arterio-
sclerosis model of the apolipoprotein E-knockout (ApoE(2/2))
mouse, administration of WIN reduced macrophageal invasion in
plaque lesions, decreased pro-inflammatory gene expression and
NF-kappaB activation in aortic tissues and reduced the size of
atherosclerotic lesions in the aorta root [58]. In experimental
autoimmune encephalomyelitis (EAE), treatment with WIN
reduced the inflammatory infiltration of brain tissue with T cells
and microglia/macrophages and reduced axonal degeneration
and demyelination [57].
In our study we found that WIN decreased the secretion of
MMP-9 protein and enzymatic activity in vitro in several cell types
of the human peripheral monocyte-macrophage-system, namely:
macrophageal differentiated U937 cells, primary peripheral
monocytes and primary osteoclasts. In murine primary microglia,
we did not detect an effect of WIN on MMP-9 secretion, whereas
our in vivo experiments using a mouse model of smoke-induced
lung inflammation demonstrated a reduced MMP-9 secretion after
Figure 8. Dephosphorylation of ERK1/2 is involved in the WIN-induced down regulation of MMP-9 mRNA, but not in the effect of
WIN on MMP-9 protein. MMP-9 quantitative Real-time PCR (bar chart) and Western blot analyses of intracellular (MMP-9 cellular) and secreted
(MMP-9 secreted) MMP-9 and for phosphorylated (pERK1/2) and unphosphorylated ERK1/2. The figure shows one representative analysis out of three.
U937-macrophages were treated with WIN (4 mM) or the pharmacological ERK1/2 phosphorylation inhibitor U-0126 (50 mM). Lane1: control; lane 2:
WIN-treatment; Lane 3: U0126-treatment; lane 4: WIN + U0126-treatment. WIN treatment resulted in a dephosphorylation of ERK associated with
inhibition of secretion, intracellular accumulation and decrease of MMP-9 mRNA (lanes 1 and 2). Inhibition of ERK1/2 phosphorylation with U-0126
decreased the level of MMP-9 mRNA significantly, but did not affect MMP-9 protein (lane 3). Treatment with WIN and U-0126 together did not
decrease MMP-9 mRNA further than caused by U-0126 alone (lines 3 and 4). Bar chart: Data are shown as means +/2 SD n= 3. *p,0.01 vs. control,
#p.0.05 according to Newman-Keuls Multiple Comparison test following ANOVA. Western blot: ß-actin 1 is from the same blot as p-EKR1/2, ß-actin 2
is from the same blot as MMP-9 and ERK1/2. Originally, the blots contained more samples. In order to arrange the figure for comparison with mRNA
quantification, blots were cut and rearranged. Original lanes can be seen in Figure S1.
doi:10.1371/journal.pone.0048272.g008
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WIN treatment in BALF. Thus, the question if microglial cells
respond to WIN with downregulation of MMP-9 secretion,
remains open and can only be solved in experiments with primary
human microglia. An influence of WIN on the regulation of
MMP-9 was described for cancer cell lines [54,86], but so far not
for cells of the immune system. Comparable concentrations of
WIN were reported to inhibit macrophageal secretion of oxidized
low-density lipoprotein-induced TNF-a and reactive oxygen
species in RAW264.7 macrophages, primary murine peritoneal
macrophages [87], and of LPS-induced nitric oxide in RAW264.7
macrophages [88]. Inhibition of MMP-9 secretion found in this
study demonstrated that the macrophageal secretion of a tissue-
destructing enzyme is also downregulated, which supports the role
of WIN as an anti-inflammatory and tissue-protective drug. Taken
together, in vitro and in vivo studies indicate that the cannabinoid
receptor agonist WIN represents a powerful possibility to reduce
and limit the activity of the monocyte-macrophage-system,
specifically the release of tissue damaging substances such as free
oxygen and nitrogen radicals and tissue destroying enzymes.
WIN-induced inhibition of MMP-9-secretion is associated with
a strong intracellular accumulation of the 92 kDa mature from of
MMP-9, which suggests an inhibitory mechanism in the secretion
process. Synthetic inhibitors of MMP-9 act by direct interaction
with MMP-9, they include the peptidomimetics batimastat and
marimastat, and the non-peptidomimetics tanomastat, prinoma-
stat and BMS-275291 [89]. Other synthetic inhibitors of MMP-9
down-regulate MMP-9-transcription, amongst these tetracycline
and its derivatives minocycline, metastat and doxycycline [90],
raloxifen [91], nobiletin [92], and rosiglitazone [93]. The
intracellular accumulation of MMP-9 in parallel with decreased
secretion as shown in our experiments has only been reported in
one previous study, in which hypoxia induced a reduction of TNF-
a-induced MMP-9 secretion in U937 monocytes [36]. In that
study the accumulation was accompanied by decreased MMP-9 in
secretory vesicles, and an enhanced surface binding of MMP-9. In
contrast to those findings, our study could not detect changes in
intracellular distribution of MMP-9 after WIN-treatment with
immunfluorescence (fig. 4). Therefore the mechanism of decrease
in MMP-9 secretion and intracellular accumulation is likely to be
different from the observation in the study mentioned above.
Importantly, WIN-induced intracellular accumulation of MMP-9
could result in a strong MMP-9 release after apotosis or necrosis of
the macrophages, which should be tested in further long-term
in vitro or in vivo studies.
Post-transcriptional regulation of MMP-9 was described for
biphosphonate clodronate [94], statins [95], and native fibronectin
[96], which regulate MMP-9 independently of mRNA levels.
Among these, an intracellular accumulation of MMP-9 has been
ruled out experimentally for fibronectin [96], but it has not been
investigated for clodronate and statins.
In our experiments we were able to confirm that MEK/ERK
signaling is involved in transcriptional regulation of MMP-9,
which has been demonstrated previously in macrophages [35,83]
as well as in other cell types, such as adult rat cardiac fibroblasts
[97]. We found surprising evidence that WIN does not use the
‘‘classical’’ cannabinoid receptors to regulate maturation and
secretion of MMP-9. Instead we observed that these effects are
mimicked by CZP and antagonized by CIC. This points to an
antagonistic action of WIN at TRPV1 as a signaling element
underlying the WIN-induced effects on MMP-9. TRPV1 plays an
important role in immune control: Previous studies using TRPV1-
deficient mice revealed protective effects of TRPV1 in mouse
models of colonic inflammation [98] and allergic contact
dermatitis [99], rendering TRPV1 as a potential pharmacological
target for the treatment of inflammatory conditions [100].
Functional antagonism of WIN on TRPV1 has already been
shown in several model systems: WIN was found to act as an
antagonist on TRPV1 in primary rat trigeminal ganglion cultures,
leading to dephosphorylation of the receptor [101] and it evoked
antihyperalgesia and antinociception via TRPV in an in vivo model
for trigenimal and dorsal root ganglia pain [102]. The antagonistic
effect of WIN on TRPV1 was also responsible for a reduction in
microglia activation in a model for age-associated brain inflam-
mation [78]. However, the protective effects of TRPV1 antag-
onisation were attributed mainly to neuronal targets rather than to
the immune system. Considering the fact that CIC is already
active on TRPV1 in low nM ranges as observed in electrophys-
iology-experimens [103,104,105], the concentration of 10 mM
used in our experiment is high. However, other effects of TRPV1
on channel activity [106,107] or on the expression of the
inflammatory mediator IL-6 [108] are induced in the mM range.
The wide range of functional CIC concentrations in different
model systems could be the consequence of different CIC
bioavailabilities. Based on our experiments, we cannot rule out
that the effects on MMP-9 are also mediated by a CZP/CIC-
Figure 9. Inhibition of MMP-9 secretion and activity and
intracellular accumulation of MMP-9 in WIN-treated activated
primary peripheral monocytes. (a) Western blot analysis of cell
lysates (MMP-9 cellular) and conditioned medium (MMP-9 secreted)
using anti-MMP-9 antibodies. The figure shows one representative
analysis out of three. WIN inhibited MMP-9 secretion and induced an
intracellular accumulation of 92 kDa MMP-9. (b) MMP-9 activity-ELISA of
conditioned medium. Upon treatment with 2 and 4 mM WIN, a
concentration-dependent reduction of MMP-9-activity was observed.
Data are shown as means +/2 SD n=3. **p,0.01 vs. control according
to Newman-Keuls Multiple Comparison test following ANOVA. (C)
Zymography of conditioned medium. Gelatinolytic activity was
inhibited by WIN-treatment. The figure shows one representative
analysis out of three.
doi:10.1371/journal.pone.0048272.g009
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sensitive element other than TRPV1. We nevertheless suggest that
a CIC/CZP-sensitive binding site is involved. The site is probably
TRPV1, which transduces anti-inflammatory signals in cells of the
monocyte-macrophage-system, which in turn down-regulates
MMP-9 maturation and secretion.
Interestingly, the endocannabinoid anandamide also induced
apoptosis in human U937 macrophages via TRPV1 [109].
Consequently, TRPV1 cannot only control and limit macrophage
activation at a certain threshold, but it also reduces its number and
concentration in inflamed tissue. We were able to demonstrate
that WIN was capable of inhibiting bone resorption by primary
Figure 10. Inhibition of MMP-9 secretion and activity and intracellular accumulation of MMP-9 in WIN-treated osteoclasts, but not
in microglia. (a) Western blot analysis of cell lysates (MMP-9 cellular) and conditioned medium (MMP-9 secreted). using anti-MMP-9-antibody and
MMP-9-activity ELISA of conditioned medium (bar chart) from osteoclasts. Upon WIN treatment (4 mM), the amount of intracellular 92 kDa-MMP-9
was enhanced, while the amount of secreted MMP-9 and the activity of MMP-9 in the conditioned medium was decreased. (b) Western blot analysis
of cell lysates (MMP-9 cellular) using anti-MMP-9-antibody and MMP-9 ELISA of conditioned medium (bar chart) from primary microglia. Size and
amount of intracellular MMP-9 were not changed after WIN-treatment (4 mM). The amount of MMP-9 in the conditioned medium increased
insignificantly. PC= positive control (U937 macrophages). The figure shows one representative analysis out of three. Data are shown as means +/2 SD
n= 3. *p,0.05, #p.0.05 vs. control according to unpaired t test.
doi:10.1371/journal.pone.0048272.g010
Figure 11. WIN reduced bone resorption and MMP-9-activity in a capsaicin sensitive manner. (a) Measurement of resorption activity of
osteoclasts using crosslaps-ELISA of conditioned medium. Treatment with WIN (4 mM) reduced the osteolytic activity compared to control cells
(vehicle treated). Additional treatment with capsaicin (CIC) antagonized this decrease. Data are shown as means +/2 SD, n = 5. (b) MMP-9-activity-
ELISA of conditioned medium of osteoclasts. Treatment with WIN (4 mM) decreased MMP-9-activity significantly compared to control cells (vehicle
treated) and this decrease was antagonized by parallel treatment with CIC. Data are shown as mean +/2 SD, n = 5. *p,0.05, #p.0.05 according to
Newman-Keuls Multiple Comparison Test following ANOVA.
doi:10.1371/journal.pone.0048272.g011
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osteoclasts. Since MMP-9 is a crucial element in bone resorption
[24] and since the extent of capsaicin-sensitivity of WIN-induced
bone protection was comparable to the extent of MMP-9
inhibition (see fig. 11), it is possible that bone protection and
MMP-9 inhibition are not only associated, but also causally linked.
Modulation of bone homeostasis by agents acting in the
cannabinoid system has been reported for CP 55,940, JWH015,
AM251 and SR144528 [24,110,111]. Furthermore, a regulatory
role of TRPV1 in bone homeostasis has been proposed, because
capsaicin promoted differentiation of osteoclasts in bone marrow
[112]. Moreover, it was suggested that capsazepine inhibits bone
resorption in RANKL-generated osteoclastic cultures [113].
Therefore, it is possible that TRPV1 and cannabinoids are
playing an important role in the regulation of bone metabolism.
We demonstrated that the cannabinoid receptor agonist WIN
reduced MMP-9 secretion in vivo and in vitro. Because reduction of
MMP-9 activity results in less tissue destruction by proteolysis of
the ECM, and subsequently in less inflammatory activation and
leukocyte recruitment [114], it represents an interesting therapeu-
tic target, not only for inflammatory conditions but also for the
inhibition of bone destruction such as during osteoporosis [24].
Because of its anti-inflammatory properties, treatment with WIN
has been studied in several models of inflammatory diseases. In a
mouse model of arteriosclerosis, the amount of macrophages in
plaque lesions was reduced [58], and in a model of PMA-induced
inflammation of ear tissue, topical application of WIN decreased
leukocyte infiltration [55]. Because MMP-9 promotes migration
and invasion of leukocytes [32,115,116,117], the diminished
leukocyte infiltration in vivo after WIN-treatment could be the
consequence of inhibited MMP-9 secretion. Inhibition of MMP-9
by WIN could also initiate neuroprotective effects: Administration
of WIN resulted in a reduced macrophageal infiltration of brain
tissue and amelioration of neuronal damage in an EAE model
[57]. MMP-9 is capable of damaging the blood brain barrier and
thereby facilitating the invasion of leukocytes that subsequently
lead to demyelination [118,119]. The proteolytic activity of MMP-
9 may also directly induce axon demyelination [120]. Therefore,
inhibition of MMP-9 secretion by WIN can be considered as
promising strategy of tissue protection during various inflamma-
tory conditions.
Other possible fields of application are inflammatory bowel
diseases, where MMP-9 is upregulated in colonic epithelium,
leading to the destruction and pathological reorganization of
epithelial tissue [47,121]. Macrophageal secreted MMP-9 is also
significantly involved in irreversible tissue destruction and
reorganization in periodontal inflammations [122,123,124]. In
humans, WIN has already been applied therapeutically to
decrease the intraocular pressure of human glaucoma resistant
to conventional therapies [125]. Systemic application of WIN is
limited by its agonistic actions on cannabinoid receptor 1 which
lead to psychotropic side effects. Another possibility is the topical
application of WIN because of its transdermal permeation [126].
Reduction of tissue destruction during inflammation and parallel
avoidance of psychotropic side effects as the consequence of
cannabinoid receptor 1 stimulation could also be achieved by the
application of other TRPV1-antagonists. TRPV1-antagonists with
a proven in vivo tolerance are for instance A-425619 (1-
Isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea) [127], or
AMG 517 (N-(4-[6-(4-trifluoromethyl-phenyl)-pyrimidin-4-yloxy]-
benzothiazol-2-yl)-acetamide I) [128].
We conclude that the control of MMP-9 in the monocyte-
macrophage system by a WIN-binding site represents a general
and pharmacologically well accessible option for tissue protection
during inflammation. Therefore, drugs acting on WIN-binding site
may possess the potential to specifically attenuate and limit tissue
damage during inflammation, without suppressing the immuno-
logical network in general.
Supporting Information
Figure S1 ß-actin controls of the Western blot in figure 8. The
demonstrated Western blot analyses had separate actin controls. In
order to arrange the figure 8 for comparison with mRNA
quantification, blots were cut and rearranged. ß-actin 1 is from the
same blot as p-EKR1/2, ß-actin 2 is from the same blot as MMP-9
and ERK1/2. Western blot analyses of intracellular (MMP-9
cellular) and secreted (MMP-9 secreted) MMP-9 and for
phosphorylated (pERK1/2) and unphosphorylated ERK1/2 are
demonstrated. U937-macrophages were treated with WIN (4 mM)
or the pharmacological ERK1/2 phosphorylation inhibitor U-
0126 or PD98059.
(TIF)
Figure 12. Treatment with WIN reduced MMP-9 protein in bronchoalveolar lavage fluid (BALF) of mice with smoke-induced lung
inflammation. Mice were exposed to air, cigarette smoke (smoke), or cigarette smoke plus i.p. treatment with 5 mg/kg/d WIN (smoke + WIN). (a)
MMP-9 protein was measured by ELISA in BALF. Cigarette smoke-exposure enhances the MMP-9-content of BALF. I.p application of WIN during
cigarette smoke-exposure reduced MMP-9 in BALF. (b) Number of white blood cells (WBCs) in BALF measured by haemocytometry. Cigarette smoke-
exposure enhanced the content of WBCs in BALF significantly. I.p. application of WIN during cigarette smoke-exposure did not alter the number of
WBCs. (c) Ratio of MMP-9/105 WBCs. The amount of MMP-9 per WBC decreased upon i.p. application of WIN significantly. Data are shown as means +/
2 SD, n = 7 (air) n = 8, (smoke), n = 9 (smoke+WIN). *p,0.05, #p.0.05 according to Newman-Keuls Multiple Comparison test following ANOVA.
doi:10.1371/journal.pone.0048272.g012
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